References

Adeno-associated virus vector as a platform for gene therapy delivery

10.1038/s41573-019-0012-9 · 2019 · External reference

Delivery of adeno-associated virus vectors to the central nervous system for correction of single gene disorders

10.3390/ijms25021050 · 2024 · External reference

Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next

10.1146/annurev-genom-102319-103602 · 2020 · External reference

Unresolved reference

2025 · External reference

Onasemnogene abeparvovec: a review in spinal muscular atrophy

10.1007/s40263-022-00941-1 · 2022 · External reference

Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase I ascending-dose study (STRONG)

10.3233/jnd-221560 · 2023 · External reference

Intrathecal onasemnogene abeparvovec in treatment-naïve patients with spinal muscular atrophy: a phase 3, randomized controlled trial

2025 · External reference

Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial

2025 · External reference

Adeno-associated virus serotype 9 antibodies in neonates and young children: Seroprevalence and kinetics

10.1016/j.omtm.2024.101344 · 2024 · External reference

Emerging issues in AAV-Mediated in vivo gene therapy

10.1016/j.omtm.2017.11.007 · 2018 · External reference

Adeno-associated virus antibody profiles in newborns, children, and adolescents

10.1128/cvi.05107-11 · 2011 · External reference

Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies

10.1016/j.omtm.2024.101273 · 2024 · External reference

Seroprevalence of adeno-associated virus types 1, 2, 3, 4, 5, 6, 8, and 9 in a Basque cohort of healthy donors

10.1038/s41598-024-66546-4 · 2024 · External reference

Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec

10.1016/j.omtm.2021.02.014 · 2021 · External reference

Prevalence of neutralizing antibodies to AAV2 and AAV9 in individuals with Niemann-Pick disease, type C1

10.1089/hum.2024.233 · 2025 · External reference

Pre-existing Anti-AAV9 antibodies in the Chinese healthy and rare disease populations: Implications for gene therapy

10.1016/j.virusres.2025.199549 · 2025 · External reference

Prevalence of neutralizing antibodies against adeno-associated virus serotypes 1, 2, and 9 in non-injected Latin American patients with heart failure-ANVIAS Study

10.3390/ijms24065579 · 2023 · External reference

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs

10.1016/j.omtm.2022.10.014 · 2022 · External reference

Neutralizing antibodies: role in immune response and viral vector based gene therapy

10.3390/ijms26115224 · 2025 · External reference

Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies

10.3389/fimmu.2014.00446 · 2014 · External reference

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

10.1038/s41591-022-01867-3 · 2022 · External reference

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

10.1038/s41591-022-01866-4 · 2022 · External reference

Quantification and comparison of anti-AAV9 and anti-AAVrh74 antibodies in plasma and human milk: Implications for AAV-based gene therapy candidacy

10.1177/22143602251324857 · 2025 · External reference

Higher seroprevalence of anti-adeno-associated viral vector neutralizing antibodies among racial minorities in the United States

10.1089/hum.2021.243 · 2022 · External reference

Kinetics of maternal antibodies against rubella and varicella in infants

10.1016/j.vaccine.2010.06.004 · 2011 · External reference